A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods:...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588704614449152 |
|---|---|
| author | Danilo Giffoni de Mello Morais Mata Rossanna C. Pezo Kelvin K. W. Chan Ines Menjak Andrea Eisen Maureen Trudeau |
| author_facet | Danilo Giffoni de Mello Morais Mata Rossanna C. Pezo Kelvin K. W. Chan Ines Menjak Andrea Eisen Maureen Trudeau |
| author_sort | Danilo Giffoni de Mello Morais Mata |
| collection | DOAJ |
| description | Background: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, <i>p</i> = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, <i>p</i> = 0.021) and HR 0.71 (0.56–0.91, <i>p</i> = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology. |
| format | Article |
| id | doaj-art-74e5b4417f9e4813bde2df5332ad35cc |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-74e5b4417f9e4813bde2df5332ad35cc2025-01-24T13:28:20ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-01321610.3390/curroncol32010006A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast CancerDanilo Giffoni de Mello Morais Mata0Rossanna C. Pezo1Kelvin K. W. Chan2Ines Menjak3Andrea Eisen4Maureen Trudeau5Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, CanadaDivision of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDivision of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDivision of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDivision of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON L8V 1C3, CanadaDivision of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaBackground: Anthracycline–taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline–taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63–0.95, <i>p</i> = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52–0.95, <i>p</i> = 0.021) and HR 0.71 (0.56–0.91, <i>p</i> = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline–taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.https://www.mdpi.com/1718-7729/32/1/6human epidermal growth factor receptor 2 negativeendocrine (hormone) receptorpaclitaxeldoxorubicinepirubicinadjuvant |
| spellingShingle | Danilo Giffoni de Mello Morais Mata Rossanna C. Pezo Kelvin K. W. Chan Ines Menjak Andrea Eisen Maureen Trudeau A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer Current Oncology human epidermal growth factor receptor 2 negative endocrine (hormone) receptor paclitaxel doxorubicin epirubicin adjuvant |
| title | A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer |
| title_full | A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer |
| title_fullStr | A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer |
| title_full_unstemmed | A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer |
| title_short | A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer |
| title_sort | real world comparison between adjuvant docetaxel with cyclophosphamide tc and anthracycline taxane chemotherapy in early her 2 negative breast cancer |
| topic | human epidermal growth factor receptor 2 negative endocrine (hormone) receptor paclitaxel doxorubicin epirubicin adjuvant |
| url | https://www.mdpi.com/1718-7729/32/1/6 |
| work_keys_str_mv | AT danilogiffonidemellomoraismata arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT rossannacpezo arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT kelvinkwchan arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT inesmenjak arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT andreaeisen arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT maureentrudeau arealworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT danilogiffonidemellomoraismata realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT rossannacpezo realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT kelvinkwchan realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT inesmenjak realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT andreaeisen realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer AT maureentrudeau realworldcomparisonbetweenadjuvantdocetaxelwithcyclophosphamidetcandanthracyclinetaxanechemotherapyinearlyher2negativebreastcancer |